Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
종목 코드 PRTA
회사 이름Prothena Corporation PLC
상장일Dec 21, 2012
CEODr. Gene G. Kinney, Ph.D.
직원 수163
유형Ordinary Share
회계 연도 종료Dec 21
주소77 Sir John Rogerson's Quay, Block C
도시DUBLIN
증권 거래소NASDAQ Global Select Consolidated
국가Ireland
우편 번호D02 VK60
전화35312362500
웹사이트https://www.prothena.com/
종목 코드 PRTA
상장일Dec 21, 2012
CEODr. Gene G. Kinney, Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음